EditFrom NeuroLex
Deferasirox
| Name: | Deferasirox |
| Description: | Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. Pharmacology: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain. Mechanism of action: Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. Drug type: Approved. Investigational. Small Molecule. Drug category: Iron Chelating Agents |
| Synonym(s): | Deferasiroxum (inn-latin), ICL 670, deferasirox, Exjade |
| Has role: | Drug |
| Super-category: | Molecule |
| URL: | http://www.drugbank.ca/drugs/DB01609 |
| Id: | CHEBI: 49005 |
| Link to OWL / RDF: | Download this content as OWL/RDF |
Facts about DeferasiroxRDF feed
| Comment | taken from DrugBank |
| CurationStatus | uncurated + |
| Curator | Ab + |
| DefiningCitation | http://www.drugbank.ca/drugs/DB01609 + |
| Definition | Deferasirox is an oral iron chelator. Its … Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose. Pharmacology: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain. Mechanism of action: Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys. Drug type: Approved. Investigational. Small Molecule. Drug category: Iron Chelating Agents cule. Drug category: Iron Chelating Agents |
| Has role | Drug + |
| Id | CHEBI: 49005 + |
| Label | Deferasirox + |
| ModifiedDate | 17 March 2010 + |
| SuperCategory | Molecule + |
| Synonym | Deferasiroxum (inn-latin) +, ICL 670 +, deferasirox +, and Exjade + |